IDEAYA Enters Collaboration With Roche To Evaluate The Efficacy And Safety Of IDE892, Its Investigational PRMT5 Inhibitor, With Roche's RG6505
IDEAYA Biosciences
هوفمان-لا روش ADR
IDEAYA Biosciences IDYA | 0.00 | |
ROCHE HOLDINGS AG RHHBY | 0.00 |
- IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma
- IDEAYA will sponsor the clinical trial, and there will be joint IDEAYA and Roche governance to oversee the study
- MTAP-deletion is estimated to occur in up to 40% of PDAC